Drugmaker Pfizer provided an updated analysis of clinical trial data for the third phase of the COVID-19 vaccine, and said that the end result of its analysis of the trial with 44,000 participants demonstrated the effectiveness of the COVID-19 vaccine by 95%. This is a better efficiency rate than previously reported by Pfizer, when it announced a 90% efficacy metric based on preliminary analysis of 3-phase trial data.
This result also comes after a preliminary data report from Moderna about their Phase 3 trial of their candidate vaccine, which they reported showed 94.5% efficacy. Pfizer and its partner BioNTech vaccine is a preventative mRNA-based treatment, similar to Moderna, and now it appears that the two should be roughly similar in effectiveness – at least initially, based on a limited sample of total cases and before peer review by the scientific community, which She did not come yet.
Pfizer data in its final analysis shows that of the total of 170 confirmed cases of COVID-19 so far out of 44,000 people who have participated in the study, 162 cases came from the placebo group while only eight were from the group of those who received the actual vaccine candidate. The company also reported that 9 out of 10 of the severe cases among those infected occurred in the placebo group, indicating that even in the rare cases where the vaccine did not prevent COVID-19 shrinking, it helped reduce its severity.
This should help Pfizer prove its case by granting an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) to be able to provide the vaccine early pending full and final approval as an emergency measure. Earlier this week, the company stated that it had already collected two-month follow-up data on participants in its trial, a component required to obtain the aforementioned approval, and is following it up with the hope of seeking an EUA “within days.” The company intends to increase production of its vaccine starting from Late this year, achieving an operating rate of 1.3 billion doses by next year.